Antivascular treatment to receive £1.4m of funding
The development of a new antivascular drug to fight cancer in dogs is to receive £1.4m in funding from Eurostars.
French-based pharmaceutical company Ecrins Therapeutics has teamed-up with Dr Barbara Kaser-Hotz from Switzerland's Animal Oncology and Imaging Centre (AOIC) and Dr Susan North from the UK's leading private Small Animal Cancer Treatment Centre (VRCC) to test and develop this new and exciting treatment option.
The company has already invested over two million euros in the development of the treatment and Eurostar's contribution will add a further 1.6 million euros (£1.4m) to the pot. The project began in April 2015 and it is hoped that the drug will come to market in the few years.
Eurostars is an organisation which supports international innovative projects led by research and development-performing small and medium sized enterprises. With its forward-thinking approach, the organisation supports the development of rapidly marketable innovative products, processes and services that help improve the daily lives of people around the world.
Ecrins Therapeutics, AOIC and VRCC came 19th out of 323 Eurostars eligible applications. They are all now looking forward to working together and playing an important contribution to the improvement of cancer treatment in dogs.
Eligible members of BEVA will be able to vote for their Council team until Monday, 17 August 2026. Members will have received an election email on 17 July.
